Immuneering Corporation (IMRX) compared with its closest peers (LYEL, UPB, CATX, GALT, CAPR). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $380.32M | -1.9 |
| Upstream Bio, Inc. (UPB) | $378.76M | -10.2 |
| Perspective Therapeutics, Inc. (CATX) | $376.70M | -2.0 |
| Galectin Therapeutics Inc. (GALT) | $372.64M | -8.6 |
| Capricor Therapeutics, Inc. (CAPR) | $366.86M | -12.8 |
| DiaMedica Therapeutics Inc. (DMAC) | $351.06M | -11.4 |
| Abeona Therapeutics Inc. (ABEO) | $347.67M | 5.2 |
| Opus Genetics, Inc. (IRD) | $336.11M | -2.5 |
| Vanda Pharmaceuticals Inc. (VNDA) | $318.12M | -2.4 |
| Rockwell Medical, Inc. (RMTI) | $315.76M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
IMRX overview · IMRX earnings · IMRX financials · IMRX KPIs · IMRX investor relations · IMRX ownership · IMRX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.